Abercrombie & Fitch upgraded at Morgan StanleyANF was upgraded from Equal-weight to Overweight, Morgan Stanley said. $56 price target. Stock appears attractive, on a sum-of-the-parts analysis.
Blackrock rated new Buy at Sterne AgeeCoverage of BLK was started with a Buy rating, Sterne Agee said. $222 price target. Recent underperformance has created an attractive buying opportunity.
Clear Channel Outdoor upgraded at WellsCCO was upgraded from Market Perform to Outperform, Wells Fargo said. Company has late-cycle exposure to the advertising recovery.
Clorox downgraded at JefferiesCLX was downgraded from Buy to Hold, Jefferies said. $67.50 price target. Company is facing higher input costs.
Clorox estimates raised at GoldmanCLX estimates were increased through 2012, Goldman Sachs said. Company is realizing higher margins. Neutral rating and $67 price target.
Salesforce.com upgraded at GoldmanCRM was upgraded to Buy, Goldman Sachs said. Estimates also raised, as the company should continue to grow sales in the SaaS market. $102 price target.
Great Plains Energy downgraded at KeybancGXP was downgraded from Buy to Hold, Keybanc said. Valuation call, as the stock has moved up through the $19.50 price target.
Hasbro rated new Buy at GoldmanCoverage of HAS was started with a Buy rating, Goldman Sachs said. Company was also placed on the Conviction List, with a $56 price target. Appears to be in the early stages of a sales growth cycle.
Hologic downgraded at Brean MurrayHOLX was downgraded from Buy to Hold, Brean Murray said. Stock appears to have limited upside from current levels.
Hospira upgraded at GoldmanHSP was upgraded from Neutral to Buy, Goldman Sachs said. $66 price target. Market is not yet pricing in the potential for positive earnings surprises.
Jarden downgraded at JefferiesJAH was downgraded from Buy to Hold, Jefferies said. $34 price target. Company is facing currency issues in Europe and higher shipping costs in China.
Kaydon downgraded at KeybancKDN was downgraded from Buy to Hold, Keybanc said. Company is guiding for flatter margins in the second half of the year.
Mattel rated new Neutral at GoldmanMAT was initiated with a Neutral rating, Goldman Sachs said. Sales expectations appear high, though the company could still deliver another year of 20% earnings growth. $27 price target.
Power Integrations upgraded at Piper JaffrayPOWI upgraded at Piper Jaffray. Rating raised to Overweight from Neutral. Maintains $43 price target and 2010 EPS estimates of $2.08.
PPG Industries rated new Equal-weight at Morgan StanleyPPG was initiated with an Equal-weight rating, Morgan Stanley said. $69 price target. Stock is already pricing in leverage to recovery in industrial production. Equal-weight rating.
Sapient coverage assumed at CitiSAPE upgraded to Buy from Hold. As media investors become more focused on Sapient's digital marketing exposure, valuation will improve, Citigroup said. Price target jumped to $14.50 from $11.
Sapient added to Conviction Buy list at GoldmanSAPE was added to the Conviction Buy List, Goldman Sachs said. Company is positioned well to benefit from a cyclical recovery in technology and marketing spending. $13 price target.
SMG was downgraded from Buy to Hold, Jefferies said. $52.50 price target. Company is facing higher plastic and paper costs.
Synovus Financial upgraded at CitiSNV upgraded to Buy from Neutral. The successfully executed $1 billion equity raise removed the key overhang for the stock, Ctigroup said.
Sonoco Products rated new Outperform at OppenheimerSON was initiated with an Outperform rating, Oppenheimer said. $40 price target. Consumer business has a robust pipeline of new products.
Valeant Pharmaceuticals upgraded at Piper JaffrayVRX upgraded at Piper Jaffray. Rating raised to Neutral from Underweight. Price target raised to $44 from $27. 2010 EPS estimates raised to $2.86 from $2.52.
ACN was removed from the Conviction Buy list, Goldman Sachs said. See more near-term upside in SAPE. $50 price target.
Anadarko Petroleum estimates boosted at Morgan Stanley
APC estimates were upped through 2011, Morgan Stanley said. Company has strong earnings momentum, despite uncertainty in the Gulf of Mexico. Equal-weight rating.
Anadarko Petroleum estimates boosted at Morgan StanleyAPC estimates were upped through 2011, Morgan Stanley said. Company has strong earnings momentum, despite uncertainty in the Gulf of Mexico. Equal-weight rating.
Arrow Electronics target, estimates boosted CitiARW price target jumped to $43 from $36.50 as 1Q10 earnings beat and optimistic outlook, Citigroup said. 2010 and 2011 EPS estimates lifted to $3.16 and $3.20, respectively. Maintain Buy rating.
Arrow Electronics numbers raised at UBSShares of ARW now seen reaching $36, according to UBS. Estimates also increased, to match the company's new guidance. Buy rating.
Avon Products estimates cut at UBSAVP estimates were lowered through 2011, UBS said. Company is seeing lower earnings in China and Venezuela, while facing extra charges for its internal investigation. Buy rating and $40 price target.
Baxter estimates, target lowered at GoldmanShares of BAX now seen reaching $52, according to Goldman Sachs. Estimates also reduced, given slower expected growth in the plasma business. Neutral rating.
Baxter estimates lowered at UBSBAX estimates were cut through 2011, UBS said. Recall of the Colleague pump will hurt sales. Buy rating and $60 price target.
Bristol-Myers estimates reduced at Morgan StanleyBMY estimates were cut through 2011, Morgan Stanley said. Company to see an impact from healthcare reform. Overweight rating.
Beazer Home price target higher at BofA/MerrillBZH price target jumped to $7 from $4.50 as balance sheet improves, Bank of America/Merrill Lynch said. Reiterate Neutral rating.
CB Richard Ellis numbers boosted at GoldmanShares of CBG now seen reaching $21, according to Goldman Sachs. Estimates also upped, given improved brokerage activity. Buy rating.
Chesapeake Energy estimates boosted at UBSCHK estimates were upped through 2011, UBS said. Company boosted its production guidance. Neutral rating and $25 price target.
Comcast estimates changed at BarclaysCMCSA 2010 and 2011 EPS estimates lowered to $1.28 and $1.48, respectively. Expect video sub losses to moderate, Barclays said. Reiterate Equal Weight rating and $20 price target.
CapitalSource added to Top Picks List at FBRCSE was added to the Top Picks List, FBR Capital Markets said. Profitability is being pushed out, but the thesis remains intact. $6.50 price target.
Dick's Sporting Goods numbers boosted at FBRShares of DKS now seen reaching $33, according to FBR Capital Markets. Estimates were also upped, following positive channel checks. Outperform rating.
Gilead estimates increased at Morgan StanleyGILD estimates were raised through 2012, Morgan Stanley said. Company continues to generate solid cash flow. Overweight rating and $48 price target.
Hersha Hospitality target, estimate higher at BofA/MerrillHT price target lifted to $7 from $6. Estimates raised through 2011 on robust NY RevPAR, Bank of America/Merrill Lynch said. Maintain Buy.
Kraft estimates lowered at Morgan StanleyKFT estimates were reduced through 2012, Morgan Stanley said. Company is facing a higher pension cost at Cadbury. Overweight rating and $32 price target.
King Pharmaceuticals target, estimates lower at BofA/MerrillKG price target trimmed by a dollar to $14. Share have been weak lately due to slow launch of Embeda and negative FDA panel meeting on Acurox, Bank of America/Merrill Lynch said. 2010 and 2011 estimates lowered. Reiterate Buy.
McKesson estimates, target upped at GoldmanMCK estimates were boosted through 2013, Goldman Sachs said. Company raised forward guidance. Neutral rating and new $70 price target.
Motorola target, estimates higher at Credit SuisseMOT price target raised by a dollar to $11 after detailed analysis of non-handset markets, Credit Suisse said. 2010 and 2011 EPS estimates lifted to 47 cents and 70 cents, respectively. Outperform rating.
Microsemi estimates, target increased at FBRMSCC estimates were raised through 2011, FBR Capital Markets said. Recent acquisition should boost growth. Outperform rating and new $25 price target.
Omnicare estimates increased at UBSOCR estimates were raised through 2011, UBS said. Stock buyback and debt refinancing should boost earnings. Buy rating and $36 price target.
Pitney Bowes estimates increased at GoldmanPBI estimates were raised through 2012, Goldman Sachs said. Company is seeing higher margins, but lower sales. Sell rating and $22 price target.
Principal Financial numbers raised at FBRShares of PFG now seen reaching $32, according to FBR Capital Markets. Estimates also increased, given better margins and asset inflows. Market Perform rating.
SuccessFactors numbers boosted at GoldmanShares of SFSF now seen reaching $25, according to Goldman Sachs. Estimates also upped, given the company's strong momentum in bookings. Buy rating.
